About Devatis, Inc.

Devatis, Inc. has been established in United States. As the parent company, DEVA Holding A.S., a long established multinational company headquartered in Istanbul, Turkey which is active since 1958 in pharmaceutical sector owns 100% of Devatis, Inc. shares. In addition to its activities in Turkey and various European and significant eastern territories, DEVA Holding A.S. has stepped into the territory of the USA by incorporating Devatis Inc.

In order to expand its services to human health in the US, Philipp D. Haas, having broad experience in pharmaceuticals business in various markets, is actively contributing to improve Devatis, Inc. and is acting as the President of Devatis Inc. which develops, markets and distributes quality branded pharmaceutical products directly.

Devatis, Inc. adheres to strict cGMP standards and has an excellent audit history with the US Food and Drug Administration (FDA). With over 60 years of combined pharmaceutical experience in public and private sectors in more than 60 countries, the leadership team is responsible for implementing business strategy assuring long-term success. Strategic partnerships are a vital component of current and future growth.

About DEVA Holding

Strong Market Presence

Established in 1958, DEVA Holding, is a multinational pharmaceutical company headquartered in Istanbul, Turkey that manufactures and sells pharmaceutical generics, formulations and active pharmaceutical ingredients (APIs). DEVA, stands for ‘Physicians, Drugs and Equipment’ in Turkish and also means ‘healing’. The main area of operations includes manufacturing and marketing human medicinal products, as well as production of veterinary medicines and medical vials.

Currently, DEVA has approximately 600 products in its portfolio, spanning in 13 therapy areas, ranging from oncology to cardiology, respiratory, and ophthalmology and it is ranked as 2nd with a 5.7% market share in unit sales (IQVIA data for 2020-end)

DEVA is maintaining the momentum of its regional growth and export operations, and has more than 800 marketing authorizations in many countries, including Switzerland and EU member states Germany, Netherlands and the UK. It also exports medicinal products and APIs to more than 50 countries. In 2017, DEVA started exporting operations to USA following the FDA approval. DEVA also has established affiliates abroad to strengthen its export operations. DEVA’s affiliates are Devatis Inc (US), Devatis Ltd (New Zealand), Devatis GmbH (Germany), Devatis AG (Switzerland), Devatis de Mexico S.DE RL. DE C.V (Mexico), Devatis Inc (Canada) and Devatis Pty Ltd (Australia).

DEVA develops high added value, innovative new forms and products with manufacturing areas and laboratories equipped with state-of-the-art technology and experience in R&D. DEVA invested 7% of its turnover to R&D activities in 2020.

The company has strong manufacturing capabilities with its certified facilities, compliant with the European GMP (Good Manufacturing Practice) and US FDA (US Food and Drug Administration) requirements, with an output capacity of 578 million units. The company’s manufacturing operations include liquids/semi-solids, solids, beta lactam 1, beta lactam 2, inhalation products, hormone products, solid oncology, liquid oncology, animal health products, active pharmaceutical ingredients and medical vials for sterile injectable products.

DEVA’s R&D center was named by the Ministry of Science, Industry and Technology as the best R&D Center in the pharmaceutical industry in 2015. The company has also been awarded by various prestigious trade magazines.

Eczacı Magazine named DEVA as the best R&D company of the year in the Golden Mortar Awards, recognizing the leading organizations, institutions and individuals in the pharmaceutical and pharmacy sector, in 2013, 2015, and 2017.

Comprehensive Product Portfolio

DEVA Holding has approximately 600 products in 13 therapeutic areas including oncology, ophthalmology and respiratory system products among others. DEVA Holding has been creating difference by releasing new products into market each year consistently.


Manufacturing Capabilities

DEVA's manufacturing capacity allows production of different pharmaceutical forms at large scales:

  • Tablets, Capsules
  • Injectable Products (Ampoules, Vials)
  • Single Dose Eye Drops
  • High-volume Parenteral Preparations
  • Eye Drops
  • Sterile Pomads
  • Gels & Ointments
  • Suspensions
  • Suppository
  • Syrups and Solutions
  • Metered-Dose Inhalers (MDI) and Dry-Powder Inhalers (DPI)

Established Quality Standards

The high quality of DEVA's production facilities are endorsed by globally recognized certification bodies:

  • EU – GMP (German Health Authority - Baden Württemberg, Portuguese Health Authority - Infarmed)
  • FDA (U.S. Food and Drug Administration)
  • MedSafe (New Zealand Medicines and Medical Devices Safety Authority)
  • ISO 9001 Quality Management System
  • ISO 27001 Information Security Management System
  • ISO 14001 Environmental Management System
  • BS OHSAS 18001 Occupational Health and Safety Management

Manufacturing Facilities

DEVA has manufacturing facilities at two locations: Cerkezkoy and Kartepe. All the facilities are endorsed by internationally recognized certifications proving the high quality standards of DEVA.

Çerkezköy Location:


  • Semi-Solid Dosage Forms:


Creams, Gels, Ointments, Suppository

  • Solid Dosage Forms:


Tablets, Capsules

  • Liquid Dosage Forms:


Solutions, Suspensions, Syrups, Solutions and Suspensions for Nebulisers

  • Separate Production Plant for soft gel capsules
  • Separate Production Plant for Metered-Dose Inhalers (MDI), Dry-Powder Inhalers (DPI)
  • Separate Production Plant for Cephalosporines (Tablets, Dry Suspensions, Sterile Powders)
  • Separate Production Plant for Penicillins (Tablets, Dry Suspensions, Sterile Powders)
  • Separate Production Plant for Hormones (Tablets, Creams, Jels, Pomades, Lotions, Sterile Liquids in Ampoules and Vials, Drops)
  • Separate Production Plant for Oncology Products (Tablets, Capsules)
  • Separate Production Plant for Steril Oncology Products (Vials)
  • Active Pharmaceutical Ingredient Synthesis (API)
  • Turkey’s Largest Logistics Centre


Kartepe Location:

  • Sterile liquids in ampoules and vials
  • Lyophilized products in vials
  • Small volume parenterals with blow fill seal technology
    • Unit doses (LDPE)
    • Multi doses (LDPE)
  • Empty medical ampoule
  • Cologne production